Literature DB >> 12234129

Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.

A Laszlo1, M Rahman, M Espinal, M Raviglione.   

Abstract

SETTING: Quality assurance for the WHO/IUATLD Global Tuberculosis Drug Resistance Surveillance Programme.
OBJECTIVE: To implement an ongoing proficiency-testing programme for drug susceptibility testing (DST) of Mycobacterium tuberculosis within the WHO/IUATLD Supranational Reference Laboratories Network (SRLN).
DESIGN: Five culture panels, each consisting of 10 duplicate drug-susceptible and drug-resistant clinical isolates (100 strains) of M. tuberculosis were tested for resistance to streptomycin (SM), isoniazid (INH), rifampicin (RMP) and ethambutol (EMB). DST procedures included the proportion, absolute concentration and resistance ratio methods, as well as the radiometric BACTEC 460 method.
RESULTS: The efficiency, sensitivity and specificity of M. tuberculosis DST as well as the intra-laboratory reproducibility showed that the laboratories tested susceptibility to RMP and to INH very reliably, with values ranging from 97% to 99%. The testing of SM and EMB was less dependable, with values ranging from 90% to 95%. The sensitivity of testing of EMB increased from 60% in Round 1 to 98% in Round 5, without a concomitant decrease in specificity.
CONCLUSIONS: This study has shown that regular proficiency testing can significantly improve the quality of DST, even in the most sophisticated TB laboratories. Mean DST efficiency levels of 92% for both SM and EMB and 97% and 99% for INH and RMP, respectively, are proposed as reasonable performance goals for the SRL network. Efficiency, consistently lower than these values, would require remedial action. Efficiency levels lower than mean -1 standard error, i.e., 80% for SM and EMB, 89% for INH and 95% for RMP, should always be considered as sub-standard performance for DST.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234129

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  35 in total

1.  Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings.

Authors:  David A J Moore; Daniel Mendoza; Robert H Gilman; Carlton A W Evans; María-Graciela Hollm Delgado; Jose Guerra; Luz Caviedes; Daniel Vargas; Eduardo Ticona; Jaime Ortiz; Giselle Soto; Jose Serpa
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Evaluation of the VersaTREK system compared to the Bactec MGIT 960 system for first-line drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  M Espasa; M Salvadó; E Vicente; G Tudó; F Alcaide; P Coll; N Martin-Casabona; M Torra; D Fontanals; J González-Martín
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

3.  Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008.

Authors:  Pawan K Angra; Thomas H Taylor; Michael F Iademarco; Beverly Metchock; J Rex Astles; John C Ridderhof
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

Review 4.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

5.  In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings.

Authors:  Norberto Símboli; Howard Takiff; Ruth McNerney; Beatriz López; Anandi Martin; Juan Carlos Palomino; Lucía Barrera; Viviana Ritacco
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Proficiency analysis of drug susceptibility testing by national-level tuberculosis reference laboratories from 1995 to 2003.

Authors:  Gill-Han Bai; Sang-Jae Kim; Chulhun L Chang
Journal:  J Clin Microbiol       Date:  2007-09-12       Impact factor: 5.948

7.  [Proposal of anti-tuberculosis regimens based on susceptibility to isoniazid and rifampicin].

Authors:  Alberto Mendoza-Ticona; David A J Moore; Valentina Alarcón; Frine Samalvides; Carlos Seas
Journal:  Rev Peru Med Exp Salud Publica       Date:  2013-04

8.  Extensively drug-resistant tuberculosis, Italy and Germany.

Authors:  Giovanni Battista Migliori; Johannes Ortmann; Enrico Girardi; Giorgio Besozzi; Christoph Lange; Daniela M Cirillo; M Ferrarese; Giuseppina De Iaco; Andrea Gori; Mario C Raviglione
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

9.  Worldwide emergence of extensively drug-resistant tuberculosis.

Authors:  N Sarita Shah; Abigail Wright; Gill-Han Bai; Lucia Barrera; Fadila Boulahbal; Nuria Martín-Casabona; Francis Drobniewski; Chris Gilpin; Marta Havelková; Rosario Lepe; Richard Lumb; Beverly Metchock; Françoise Portaels; Maria Filomena Rodrigues; Sabine Rüsch-Gerdes; Armand Van Deun; Veronique Vincent; Kayla Laserson; Charles Wells; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia.

Authors:  Yanina Balabanova; Francis Drobniewski; Vladyslav Nikolayevskyy; Annika Kruuner; Nadezhda Malomanova; Tatyana Simak; Nailya Ilyina; Svetlana Zakharova; Natalya Lebedeva; Heather L Alexander; Rick O'Brien; Hojoon Sohn; Anastasia Shakhmistova; Ivan Fedorin
Journal:  PLoS One       Date:  2009-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.